Cereno Scientific submits application for the start of clinical Phase II study to Bulgarian authorities
Earlier in May 2019, Cereno Scientific announced that the company had submitted an application for a clinical Phase II study with the drug candidate CS1 to the Russian authorities. Today, the company is announcing that an application has also been submitted to the authorities in Bulgaria.“We have worked hard to be able to complete our applications to both Russia and Bulgaria, the two countries where the study will be performed. Now we look forward to obtaining the approval of said authorities during the fall this year and subsequently to initiate the study, which is expected to take place